995 related articles for article (PubMed ID: 22329651)
1. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.
de la Monte SM
Curr Alzheimer Res; 2012 Jan; 9(1):35-66. PubMed ID: 22329651
[TBL] [Abstract][Full Text] [Related]
2. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.
de la Monte SM
Drugs; 2012 Jan; 72(1):49-66. PubMed ID: 22191795
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.
de la Monte SM
Front Biosci (Elite Ed); 2012 Jan; 4(4):1582-605. PubMed ID: 22201977
[TBL] [Abstract][Full Text] [Related]
4. Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.
de la Monte SM
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1954-60. PubMed ID: 25088942
[TBL] [Abstract][Full Text] [Related]
5. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
6. Insulin signaling: An opportunistic target to minify the risk of Alzheimer's disease.
Pardeshi R; Bolshette N; Gadhave K; Ahire A; Ahmed S; Cassano T; Gupta VB; Lahkar M
Psychoneuroendocrinology; 2017 Sep; 83():159-171. PubMed ID: 28624654
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder.
Kshirsagar V; Thingore C; Juvekar A
Metab Brain Dis; 2021 Jan; 36(1):67-83. PubMed ID: 32986168
[TBL] [Abstract][Full Text] [Related]
8. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.
Rivera EJ; Goldin A; Fulmer N; Tavares R; Wands JR; de la Monte SM
J Alzheimers Dis; 2005 Dec; 8(3):247-68. PubMed ID: 16340083
[TBL] [Abstract][Full Text] [Related]
9. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis.
Bosco D; Fava A; Plastino M; Montalcini T; Pujia A
J Cell Mol Med; 2011 Sep; 15(9):1807-21. PubMed ID: 21435176
[TBL] [Abstract][Full Text] [Related]
10. How does brain insulin resistance develop in Alzheimer's disease?
De Felice FG; Lourenco MV; Ferreira ST
Alzheimers Dement; 2014 Feb; 10(1 Suppl):S26-32. PubMed ID: 24529521
[TBL] [Abstract][Full Text] [Related]
11. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?
Steen E; Terry BM; Rivera EJ; Cannon JL; Neely TR; Tavares R; Xu XJ; Wands JR; de la Monte SM
J Alzheimers Dis; 2005 Feb; 7(1):63-80. PubMed ID: 15750215
[TBL] [Abstract][Full Text] [Related]
12. How Can Insulin Resistance Cause Alzheimer's Disease?
Yoon JH; Hwang J; Son SU; Choi J; You SW; Park H; Cha SY; Maeng S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834911
[TBL] [Abstract][Full Text] [Related]
13. Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease.
de la Monte SM; Tong M; Schiano I; Didsbury J
J Alzheimers Dis; 2017; 55(2):849-864. PubMed ID: 27802237
[TBL] [Abstract][Full Text] [Related]
14. Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.
Kamat PK; Kalani A; Rai S; Tota SK; Kumar A; Ahmad AS
Mol Neurobiol; 2016 Sep; 53(7):4548-62. PubMed ID: 26298663
[TBL] [Abstract][Full Text] [Related]
15. Brain metabolic dysfunction at the core of Alzheimer's disease.
de la Monte SM; Tong M
Biochem Pharmacol; 2014 Apr; 88(4):548-59. PubMed ID: 24380887
[TBL] [Abstract][Full Text] [Related]
16. Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease.
Sun Y; Ma C; Sun H; Wang H; Peng W; Zhou Z; Wang H; Pi C; Shi Y; He X
J Diabetes Res; 2020; 2020():4981814. PubMed ID: 32083135
[TBL] [Abstract][Full Text] [Related]
17. Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets.
Hamzé R; Delangre E; Tolu S; Moreau M; Janel N; Bailbé D; Movassat J
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499613
[TBL] [Abstract][Full Text] [Related]
18. The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications.
Zemva J; Schubert M
CNS Neurol Disord Drug Targets; 2014 Mar; 13(2):322-37. PubMed ID: 24059318
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
20. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
